Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma

Abstract

Vascular abnormalities in scleroderma are fundamental to the pathogenesis of this disease. The objective of this study was to characterize dermal microvascular endothelial cells (DMEC) isolated from scleroderma patients with respect to growth and expression of the constitutive form of endothelial nitric oxide synthase (eNOS). DMEC from patients with both systemic sclerosis (SSc) and localized scleroderma (Loc Scl) contained small intact microvascular structures in contrast to single cell isolations obtained from control skin. Immunoaffinity selection on anti-PECAM-1 beads yielded pure populations of DMEC expressing normal markers. While the morphology and initial growth of SSc DMEC closely paralleled control cells, the growth of SSc DMEC decreased with time in culture (doubling time of 3 days vs. 5 days). Expression of ecNOS mRNA was reduced in both Loc Scl and SSc as shown by semi-quantitative RT-PCR (p, 0.001). Western blots showed variable but generally lower ecNOS protein levels and decreased levels of nitrogen oxides in media were found from both SSc and Loc Scl relative to control cells. The results indicate an intrinsic defect in the mechanism of nitric oxide production in DMEC isolated from scleroderma patients and suggest its possible involvement in the pathophysiology of scleroderma.

Keywords

constitutive endothelial-type nitric oxide synthase human dermal microvascular endothelial cells localized scleroderma systemic scleroderma

References

Smiley JD. Southwestern internal medicine conference: the many faces of scleroderma. Am J Med Sci 1992; 304: 319-333.

Fleischmajer R , Perlish JS. Capillary alterations in scleroderma. JAm Acad Dermatol 1980; 2: 161-170.

Maricq H , LeRoy E , D’Angelo W. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 1980; 23: 183-189.

Norton W , Hurd E , Lewis D et al. Evidence of microvascular injury in scleroderma and systemic lupus erythematosus: quantitative study of the microvascular bed. J Lab Clin Med 1968; 71: 919-933.

Herron GS , Romero LI. Vascular abnormalities in scleroderma. Semin Cutan Med Surg 1998; 17: 12-17.

Belch J. Raynaud’s phenomenon: its relevance to scleroderma. Ann Rheum Dis 1991; 50: 839-845.

Hahn M , Heubach T , Steins A , Jünger M. Hemodynamics in nailfold capillaries of patients with systemic scleroderma: synchronous measurements of capillary blood pressure and red blood cell velocity. J Invest Dermatol 1998; 110: 982-985.

Kadono T , Kikuchi K , Sato S , Soma Y , Tamaki K , Takehara K. Elevated plasma endothelin levels in systemic sclerosis. Arch Dermatol Res 1995; 287: 439-442.

Knock G , Terenghi G , Bunker C. Characterization of endothelin binding sites in human skin and their regulation in primary Raynaud’s phenomenon and systemic sclerosis. J Invest Dermatol 1993; 101: 73-78.

10.

Yamane K , Kashiwagi H , Suzuki N. Elevated plasma levels of endothelin-1 in systemic sclerosis. Arthritis Rheum 1991; 34: 243-244.

11.

Wigley F , Flavahan N. Raynaud’s phenomenon. Rheum Dis Clin North Am 1996; 22: 765-781.

12.

Kahaleh B. The vascular endothelium in scleroderma. Int Rev Immunol 1995; 12: 227-245.

13.

Cooke JP , Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Ann Rev Med 1997; 48: 489-509.

14.

Candipan RC , Wang BY , Buitrago R , Tsao PS , Cooke JP. Regression or progression. Dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol 1996; 16: 44-50.

15.

Cooke JP , Singer AH , Tsao P , Zera P , Rowan RA , Billingham ME. Antiatherogenic effects of l-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992; 90: 1168-1172.

16.

von der Leyen HE , Gibbons GH , Morishita R et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Nat Acad Sci USA 1995; 92: 1137-1141.

17.

Kahaleh B , Fan P-S , Matucci-Cerinic M , Stefanovic-Racic M , Ignarro L. Study of endothelial dependent relaxation in scleroderma. Arthritis Rheum 1991; 34: 978-983.

18.

Agostini A , Marasini B , Biondy M et al. l-Arginine therapy in Raynaud’s phenomenon. Int J Clin Lab Res 1991; 21: 202-203.

19.

Khan F , Litchfield S , McLaren M , Veale D , Littleford R , Belch J. Oral l-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud’s phenomenon. Arthritis Rheum 1997; 40: 352-357.

20.

Kharitonov SA , Cailes JB , Black CM , du Bois RM , Barnes PJ. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 1997; 52: 1051-1055.

21.

Yamamoto T , Katayama I , Nishioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 1998; 25: 314-317.

22.

Karasek MA. Microvascular endothelial cell culture. J Invest Dermatol 1989; 93: 33S-38S.

23.

Normand J , Karasek MA. A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin. In Vitro Cell Dev Biol Anim 1995; 31: 447-455.

24.

Romero LI , Zhang DN , Herron GS , Karasek MA. Interleukin-1 induces major phenotypic changes in human skin microvascular endothelial cells. J Cell Physiol 1997; 173: 84-92.

25.

Hewett PW , Murray JC. Immunomagnetic purification of human microvessel endothelial cells using Dynabeads coated with monoclonal antibodies to PECAM-1. Eur J Cell Biol 1993; 62: 451-454.

26.

Chan VT , Zhang DN , Nagaravapu U , Hultquist K , Romero LI , Herron GS. Membrane-type matrix metalloproteinases in human dermal microvascular endothelial cells: expression and morphogenetic correlation. J Invest Dermat 1998; 111: 1153-1159.

27.

Tsao PS , McEvoy ML , Drexler H , Butcher EC , Cooke JP. Exnhanced endothelial adhesiveness in hypercholesterolemia is attenuated by l-arginine. Circulation 1994; 89: 2176-2182.

28.

Fukuto JM. Chemistry of nitric oxide: biologically relevant aspects. Adv Pharmacol 1995; 34: 1-15.

29.

Silver R. Scleroderma. Clinical problems/the lungs. Rheum Dis Clin North Am 1996; 22: 825-840.

30.

Chatziantoniou C , Boffa J-J , Ardaillou R , Dussaule J-C. Nitric oxide inhibition induces early activation of Type 1 collagen gene in renal resistance vessels and glomeruli in transgenic mice. J Clin Invest 1998; 101: 2780-2789.

31.

Lee PC , Salyapongse AN , Bragdon GA et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol 1999; 277: H1600-H1608.

32.

Fleischmajer R , Perlish JS. Immunological modulation of dermal fibroblasts in scleroderma. Immunol Ser 1989; 46: 605-624.

33.

Prescott R , Freemont A , Jones C , Hoyland J , Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992; 166: 255-263.

34.

Kirk TZ , Mark ME , Chua CC , Chua BH , Mayes MD. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 1995; 270: 3423-3428.

35.

Sappino A. Smooth muscle differentiation in scleroderma fibroblastic cells. Am J Pathol 1990; 137: 585-591.

36.

Kikuchi K , Kadono T , Furue M , Tamaki K. Tissue inhibitor of metal-loproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol 1997; 108: 281-284.

37.

Mattila L , Airola K , Ahonen M. Activation of tissue inhibitor of metal-loproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol 1998; 110: 416-421.

38.

Denton CP , Xu S , Welsh KI , Pearson JD , Black CM. Scleroderma fibroblast phenotype is modulated by endothelial cell co-culture. J Rheumatol 1996; 23: 633-638.

39.

Jimenez SA , Christner P. Animal models of systemic sclerosis. Clin Dermatol 1994; 12: 425-436.

40.

Leroy E. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974; 22: 880-889.

41.

Kräling BM , Jimenez SA , Sorger T , Maul GG. Isolation and characterization of microvascular endothelial cells from the adult human dermis and from skin biopsies of patients with systemic sclerosis. Lab Invest 1994; 71: 745-754.

42.

Wang R , Ghahary A , Shen YJ , Scott PG , Tredget EE. Nitric oxide synthase expression and nitric oxide production are reduced in hyper-trophic scar tissue and fibroblasts. J Invest Dermatol 1997; 108: 438-444.

43.

Arnal JF , Yamin J , Dockery S , Harrison DG. Regulation of endothelial nitric oxide synthase mRNA, protein, and activity during cell growth. Am J Physiol 1994; 267: C1381-C1388.

44.

Phelan MW. Hypoxia decreases constitutive nitric oxide synthase transcript and protein in cultured endothelial cells. J Cell Physiol 1996; 167: 469-476.

45.

Lamas S , Marsden PA , Li GK , Tempst P , Michel T. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci USA 1992; 89: 6348-6352.

46.

Nishida K , Harrison DG , Navas JP et al. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest 1992; 90: 2092-2096.

47.

Yoshizumi M , Perrella MA , Burnett JC Jr , Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205-209.

48.

Inoue N , Venema RC , Sayegh HS , Ohara Y , Murphy TJ , Harrison DG. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1. Arterioscler Thromb Vasc Biol 1995; 15: 1255-1261.

49.

Marsden PA , Heng HH , Scherer SW et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478-17488.

50.

Hood JD , Meininger CJ , Ziche M , Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274: H1054-H1058.

51.

Murohara T , Asahara T , Silver M et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101: 2567-2578.

52.

Forstermann U , Kleinert H. Nitric oxide synthase: expression and expressional control of the three isoforms. Naunyn Schmiedebergs Arch Pharmacol 1995; 352: 351-364.

53.

Geller D. Molecular biology of nitric oxide synthase. Cancer Metastasis Rev 1998; 17: 7-23.

54.

Bull R. Neuropeptides induce release of nitric oxide from human dermal microvascular endothelial cells. J Invest Dermatol 1996; 106: 635-660.

55.

García-Cardeña G , Fan R , Stern DF , Liu J , Sessa WC. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem 1996; 271: 27237-27240.

56.

Morbidelli L , Chang CH , Douglas JG , Granger HJ , Ledda F , Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996; 270: H411-H115.

57.

Ziche M. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous. Circ Res 1993; 80: 845-852.

58.

Ziche M , Morbidelli L , Choudhuri R et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 99: 2625-2634.

59.

Tsurumi Y , Murohara T , Horowitz JR , Silver M. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1997; 97: 99-107.

60.

Noiri E , Lee E , Testa J et al. Podokinesis in endothelial cell migration: role of nitric oxide. Am J Physiol 1998; 274: C236-C244.

61.

Sgonc R , Gruschwitz MS , Dietrich H , Recheis H , Gerschwin ME , Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98: 785-792.

62.

Dimmeler S , Haendeler J , Nehls M , Zeiher AM. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1 beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like pro-teases. J Exp Med 1997; 185: 601-607.

63.

Tzeng E , Kim Y-M , Pitt B , Lizonova A , Kovesdi I , Billiar TR. Aden-oviral transfer of the inducible nitric oxide synthetase gene blocks endothelial cell apoptosis. Surgery 1997; 122: 255-263.

64.

Murrell GA , Jang D , Williams RJ. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995; 206: 15-21.

65.

Kolpakov V , Gordon D , Kulik TJ. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res 1995; 76: 305-309.

66.

Numaguchi K , Egashira K , Takemoto M et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995; 26: 957-962.

67.

Myers P. Vascular endothelial cell regulation of extracellular matrix collagen: role of nitric oxide. Arterioscler Thromb Vasc Biol 1998; 18: 717-722.

68.

Bruch-Gerharz D , Ruzicka T , Kolb-Bachofen V. Nitric oxide in human skin: current status and future prospects. J Invest Dermatol 1998; 110: 1-7.

69.

Belmont H , Levartovsky D , Goel A et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1810-1816.

70.

Wilcox J , Subramanian R , Sundell C et al. Expression of multiple insoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997; 17: 2479-2488.

71.

Shimizu K , Naito S , Urata Y , Sekine I , Kondo T , Katayama I. Inducible nitric oxide synthase is expressed in granuloma pyogenicum. Br J Dermatol 1998; 138: 769-773.

72.

Rowe A , Farrell A , Bunker C. Constitutive endothelial and inducible nitric oxide synthase in inflammatory dermatoses. Br J Dermatol 1997; 136: 18-23.

73.

Kroll J , Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptors-2. Biochem Biophys Res Commun 1998; 252: 743-746.

74.

Orpana A , Ranta V , Mikkola T , Viinikka L , Ylikorkala O. Inducible nitric oxide and prostacyclin productions are differently controlled by extracellular matrix and cell density in human vascular endothelial cells. J Cell Biochem 1997; 64: 538-546.

75.

Muijsers RB , Folkerts G , Henricks PA , Sadeghi-Hashjin G , Nijkamp FP. Peroxynitrite: a two-faced metabolite of nitric oxide. Life Sci 1997; 60: 1833-1845.